Format

Send to

Choose Destination
Mol Neurobiol. 2020 Feb;57(2):1259-1280. doi: 10.1007/s12035-019-01820-5. Epub 2019 Nov 12.

Molecular Approaches for the Treatment of Pompe Disease.

Author information

1
Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy.
2
Neurology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
3
Neuromuscular and Rare Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
4
Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy. Stefania.corti@unimi.it.
5
Neurology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Stefania.corti@unimi.it.

Abstract

Glycogen storage disease type II (GSDII, Pompe disease) is a rare metabolic disorder caused by a deficiency of acid alpha-glucosidase (GAA), an enzyme localized within lysosomes that is solely responsible for glycogen degradation in this compartment. The manifestations of GSDII are heterogeneous but are classified as early or late onset. The natural course of early-onset Pompe disease (EOPD) is severe and rapidly fatal if left untreated. Currently, one therapeutic approach, namely, enzyme replacement therapy, is available, but advances in molecular medicine approaches hold promise for even more effective therapeutic strategies. These approaches, which we review here, comprise splicing modification by antisense oligonucleotides, chaperone therapy, stop codon readthrough therapy, and the use of viral vectors to introduce wild-type genes. Considering the high rate at which innovations are translated from bench to bedside, it is reasonable to expect substantial improvements in the treatment of this illness in the foreseeable future.

KEYWORDS:

Alpha-glucosidase (GAA); Antisense oligonucleotides; GSDII; Gene therapy; Molecular therapy; Pompe disease; Therapy

PMID:
31713816
DOI:
10.1007/s12035-019-01820-5

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center